Novo Nordisk/X
Aug 2, 2025, 03:50
FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
Novo Nordisk US has shared a proud post on X:
“PRESS: Novo Nordisk receives US FDA approval for a new indication for a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. ”
To learn more, follow the link.
Stay informed with Hemostasis Today.
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH
-
Oct 16, 2026, 10:07Habib Bennaceur: Building a Stronger Care Pathway for Sickle Cell Disease in India
-
Oct 16, 2026, 09:59Tareq Abadl: A Simple Guide to Blood Collection Tubes
-
Oct 16, 2026, 09:50Mona Alfaraj: Distinguishing HCL from SMZL in Bone Marrow
-
Oct 16, 2026, 09:44New International Consensus on Covert Brain Infarction – International Journal of Stroke
-
Oct 16, 2026, 06:17Neha Rastogi Panda: Precision Diagnosis and Organ Preservation in Splenic Abscess
-
Oct 16, 2026, 05:53Alejandro González Veliz: Looking Beyond Coronary Anatomy to Understand Ischemia
-
Oct 16, 2026, 04:16Asmaa M. Gouda: Advancing Blood Bank Leadership at Alexandria University Hospitals
-
Oct 16, 2026, 03:52Saja Al-Zamili: Minimally Invasive Hematoma Evacuation in Intracerebral Hemorrhage